Xenon filed a 2025 operating loss of $373.1 million, a 2025 net loss of $345.9 million and Q1 2026 cash of $545.9 million. The thesis depends on clinical execution, regulatory progress and how long the balance sheet can fund development.
The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.
